<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098979</url>
  </required_header>
  <id_info>
    <org_study_id>17582</org_study_id>
    <secondary_id>2016-004062-26</secondary_id>
    <nct_id>NCT03098979</nct_id>
  </id_info>
  <brief_title>A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>PANACHE</acronym>
  <official_title>A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to find the optimal dose of once daily oral neladenoson
      bialanate (BAY1067197) when given in addition to appropriate therapy for specific
      comorbidities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">May 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in 6-minute Walking Distance (6MWD) After 20 Weeks of Treatment</measure>
    <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
    <description>The 6MWD test is designed to evaluate a subject's exercise capacity while performing an everyday activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Weekly Percentage of Maximum Possible Recorded Activity Intensity</measure>
    <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
    <description>AVIVO™ Mobile Patient Management System, a wearable wireless device worn by the subject, was used to monitor subjects' cardiovascular status. The patient's everyday physical activity e.g. duration, intensity, was also tracked by the AVIVO device. For Activity Intensity, the Unit of Measure is &quot;percentage of maximum activity&quot;, and length of intervals is &quot;daily&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured Values (Log Transformed) and Absolute Change in NT-proBNP From Baseline to 20 Weeks</measure>
    <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
    <description>NT-proBNP = N-terminal pro-hormone b-type natriuretic peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured Values (Log-transformed) and Absolute Change in High Sensitivity Troponin T (Hs-TNT) From Baseline to 20 Weeks</measure>
    <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
    <description>High sensitivity troponin T (hs-TNT) was measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured Values and Absolute Change in 3 Scores From Kansas City Cardiomyopathy Questionnaire (KCCQ) From Baseline to 20 Weeks: Overall Summary Score, Physical Limitation Score and Total Symptom Score</measure>
    <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
    <description>The KCCQ is the leading health-related quality-of-life measure for patients with chronic heart failure (CHF). It is a 23-item questionnaire that independently measures the impact of patient's heart failure (HF), or its treatment, on 7 distinct domains: 1) Symptom Frequency 2) Symptom Burden 3) Physical Limitation 4) Quality of Life 5) Social Limitations 6) Self-efficacy 7) Symptoms Stability.
Overall summary score= mean score of (symptom frequency + symptom burden+ physical limitation + quality of life + social limitation); scores on a scale of 0 to 100, higher scores means better outcome; Physical Limitation: scores on a scale of 0 to 100, higher scores means better outcome; Total symptom score=mean score of (symptom frequency + symptom burden): scores on a scale of 0 to 100, higher scores means better outcome.
Positive change means improvement and negative change means deterioration.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic heart failure with preserved ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic heart failure with preserved ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic heart failure with preserved ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (30 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic heart failure with preserved ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (40 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic heart failure with preserved ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Chronic heart failure with preserved ejection fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neladenoson bialanate (BAY1067197)</intervention_name>
    <description>5 mg orally once daily for 20 weeks</description>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neladenoson bialanate (BAY1067197)</intervention_name>
    <description>10 mg orally once daily for 20 weeks</description>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (10 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neladenoson bialanate (BAY1067197)</intervention_name>
    <description>20 mg orally once daily for 20 weeks</description>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (20 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neladenoson bialanate (BAY1067197)</intervention_name>
    <description>30 mg orally once daily for 20 weeks</description>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (30 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neladenoson bialanate (BAY1067197)</intervention_name>
    <description>40 mg orally once daily for 20 weeks</description>
    <arm_group_label>Neladenoson bialanate (BAY1067197) (40 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally once daily for 20 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 45 years and older

          -  Diagnosis of chronic heart failure, NYHA (New York Heart Association) class II-IV,
             LVEF (left ventricular ejection fraction) ≥ 45% and elevated NT-proBNP

        Exclusion Criteria:

          -  Acute decompensated heart failure within the past 4 weeks

          -  Inability to exercise

          -  Previous diagnosis of HFrEF (heart failure with reduced ejection fraction) (LVEF &lt;
             40%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Heart &amp; Vascular, PC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BryanLGH Medical Center East</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum St. Pölten</name>
      <address>
        <city>St. Pölten</city>
        <state>Niederösterreich</state>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Josef Braunau</name>
      <address>
        <city>Braunau</city>
        <state>Oberösterreich</state>
        <zip>5280</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hietzing</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de la Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik</name>
      <address>
        <city>Pernik</city>
        <zip>2300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Actrive Treatm of Card - Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Cardiohelp</name>
      <address>
        <city>Sofia</city>
        <zip>1142</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NMTH Tzar Boris III</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Tsaritsa Joanna-ISUL EAD Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCOMH Preventsia-2000</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz und Elisabeth Hospital, Kathol. Klinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Dresden GmbH</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt GmbH</name>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum (CVK)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KAT General Hospital of Athens</name>
      <address>
        <city>Kifisia / Athens</city>
        <state>Attica</state>
        <zip>14561</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Gennimatas General State Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chalkida</name>
      <address>
        <city>Chalkida</city>
        <zip>34100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konstantopoulio General Hospital of Nea Ionia - Agia Olga</name>
      <address>
        <city>Nea Ionia / Athens</city>
        <zip>142 33</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklipieion General Hospital of Voulas</name>
      <address>
        <city>Voula</city>
        <zip>16673</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>3810101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corporation</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital Mount Scopus</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <zip>6093000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAS 3 Friuli Alto Medio Collin</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Sassari</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL Toscana Sud-Est</name>
      <address>
        <city>Arezzo</city>
        <state>Toscana</state>
        <zip>52040</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chuno kosei Hospital</name>
      <address>
        <city>Seki</city>
        <state>Gifu</state>
        <zip>501-3802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Prefectural Amagasaki General Medical Center</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kanazawa Medical Center</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Fujisawa Tokushukai Hospital</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R.I.A.C Naha City Hospital</name>
      <address>
        <city>Naha</city>
        <state>Okinawa</state>
        <zip>902-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kishiwada Tokushukai Hospital</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takatsuki Red Cross Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minamino Cardiovascular Hospital</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui Prefectural Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>910-8526</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Rosai Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>702-8055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima Prefectural Central Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8539</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Zachodni w Grodzisku Mazowieckim</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. J. Dietla</name>
      <address>
        <city>Krakow</city>
        <zip>31-121</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im. dr Wl. Bieganskiego</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>109 Szpital Wojskowy z przychodnia SPZOZ</name>
      <address>
        <city>Szczecin</city>
        <zip>70-965</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wolski im. dr Anny Gostynskiej SPZOZ</name>
      <address>
        <city>Warszawa</city>
        <zip>02-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IV Wojskowy Szpital Kliniczny z Poliklinika, SPZOZ</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUC - Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHLO - Hospital São Francisco Xavier</name>
      <address>
        <city>Lisboa</city>
        <zip>1449-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Luz</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUP, EPE - Hospital de Santo Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sanitas La Zarzuela</name>
      <address>
        <city>Aravaca</city>
        <state>Madrid</state>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Virgen de la Arrixaca&quot;</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <results_first_submitted>May 23, 2019</results_first_submitted>
  <results_first_submitted_qc>July 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>Heart Failure with Preserved Ejection Fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03098979/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03098979/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 76 study centers in 12 countries, between 10 May 2017 (first patient first visit) and 20 June 2018 (last patient last visit)</recruitment_details>
      <pre_assignment_details>A total of 339 subjects entered the screening period, of whom 34 withdrew before randomization. The remaining 305 subjects were randomized and received at least one dose of study drug</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subjects received placebo matched to neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="P2">
          <title>Neladenoson Bialanate 5 mg</title>
          <description>Subjects received 5 milligrams (mg) of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="P3">
          <title>Neladenoson Bialanate 10 mg</title>
          <description>Subjects received 10 mg of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="P4">
          <title>Neladenoson Bialanate 20 mg</title>
          <description>Subjects received 20 mg of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="P5">
          <title>Neladenoson Bialanate 30 mg</title>
          <description>Subjects received 30 mg of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="P6">
          <title>Neladenoson Bialanate 40 mg</title>
          <description>Subjects received 40 mg of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="41"/>
                <participants group_id="P6" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Subjects received placebo matched to neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="B2">
          <title>Neladenoson Bialanate 5 mg</title>
          <description>Subjects received 5 milligrams (mg) of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="B3">
          <title>Neladenoson Bialanate 10 mg</title>
          <description>Subjects received 10 mg of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="B4">
          <title>Neladenoson Bialanate 20 mg</title>
          <description>Subjects received 20 mg of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="B5">
          <title>Neladenoson Bialanate 30 mg</title>
          <description>Subjects received 30 mg of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="B6">
          <title>Neladenoson Bialanate 40 mg</title>
          <description>Subjects received 40 mg of neladenoson bialanate tablets orally for 20 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="51"/>
            <count group_id="B7" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.1" spread="8.0"/>
                    <measurement group_id="B2" value="74.3" spread="9.3"/>
                    <measurement group_id="B3" value="73.5" spread="9.9"/>
                    <measurement group_id="B4" value="71.4" spread="6.8"/>
                    <measurement group_id="B5" value="76" spread="9.4"/>
                    <measurement group_id="B6" value="73.7" spread="8.3"/>
                    <measurement group_id="B7" value="73.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVEF</title>
          <description>Left ventricular ejection fraction (LVEF) is defined as the fraction of blood being pumped out of the left ventricle of the heart with each contraction.</description>
          <population>Included subjects with valid baseline value for this characteristic</population>
          <units>percentage of blood ejected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="32"/>
                    <count group_id="B5" value="32"/>
                    <count group_id="B6" value="33"/>
                    <count group_id="B7" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.09" spread="8.68"/>
                    <measurement group_id="B2" value="56.54" spread="9.62"/>
                    <measurement group_id="B3" value="53.78" spread="11.6"/>
                    <measurement group_id="B4" value="57.3" spread="10.4"/>
                    <measurement group_id="B5" value="59.43" spread="8.72"/>
                    <measurement group_id="B6" value="52.3" spread="12.76"/>
                    <measurement group_id="B7" value="56.09" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NT-proBNP</title>
          <description>N-terminal pro-hormone b-type natriuretic peptide</description>
          <population>Included subjects with valid baseline value for this characteristic</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="42"/>
                    <count group_id="B5" value="39"/>
                    <count group_id="B6" value="44"/>
                    <count group_id="B7" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="882.0" lower_limit="54" upper_limit="3034"/>
                    <measurement group_id="B2" value="1013.0" lower_limit="136" upper_limit="5709"/>
                    <measurement group_id="B3" value="1000.0" lower_limit="116" upper_limit="3547"/>
                    <measurement group_id="B4" value="834.5" lower_limit="173" upper_limit="6003"/>
                    <measurement group_id="B5" value="626.0" lower_limit="78" upper_limit="3043"/>
                    <measurement group_id="B6" value="886.5" lower_limit="60" upper_limit="8170"/>
                    <measurement group_id="B7" value="869.0" lower_limit="54" upper_limit="8170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA class</title>
          <description>NYHA classes: I: No limitation of physical activity (PA). Ordinary PA does not cause undue fatigue, palpitation, dyspnea, or anginal pain II: Slight limitation of PA; comfortable at rest. Ordinary PA results in fatigue, palpitation, dyspnea, or anginal pain III: Marked limitation of PA; comfortable at rest. Less than ordinary PA causes fatigue, palpitation, dyspnea, or anginal pain IV: Inability to carry on any PA without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any PA is undertaken, discomfort is increased</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III/IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical history: diabetes</title>
          <description>Subjects with medical history of Type 2 diabetes mellitus</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical history: Atrial fibrillation</title>
          <description>Subjects with medical history of Atrial fibrillation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical history: hypertension</title>
          <description>Subjects with medical history of hypertension</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <description>eGFR = estimated glomerular filtration rate</description>
          <units>mL/min/1.73 square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" spread="17.9"/>
                    <measurement group_id="B2" value="52.6" spread="17.1"/>
                    <measurement group_id="B3" value="61.0" spread="24.2"/>
                    <measurement group_id="B4" value="57.1" spread="17.3"/>
                    <measurement group_id="B5" value="57.5" spread="18.2"/>
                    <measurement group_id="B6" value="60.0" spread="17.5"/>
                    <measurement group_id="B7" value="59.1" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6MWD</title>
          <description>6MWD = six-minute walking distance</description>
          <units>meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="51"/>
                    <count group_id="B7" value="305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="322.8" spread="97.1"/>
                    <measurement group_id="B2" value="311.6" spread="108.2"/>
                    <measurement group_id="B3" value="295.8" spread="110.4"/>
                    <measurement group_id="B4" value="324.5" spread="105"/>
                    <measurement group_id="B5" value="321.1" spread="93.4"/>
                    <measurement group_id="B6" value="347.2" spread="94.5"/>
                    <measurement group_id="B7" value="321.5" spread="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in 6-minute Walking Distance (6MWD) After 20 Weeks of Treatment</title>
        <description>The 6MWD test is designed to evaluate a subject's exercise capacity while performing an everyday activity.</description>
        <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
        <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure, and it also included subjects who were censored due to cardiovascular (CV) death or hospitalization for heart failure (HF) that prevented assessment of efficacy at 20 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects received placebo matched to neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Neladenoson Bialanate 5 mg</title>
            <description>Subjects received 5 milligrams (mg) of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O3">
            <title>Neladenoson Bialanate 10 mg</title>
            <description>Subjects received 10 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O4">
            <title>Neladenoson Bialanate 20 mg</title>
            <description>Subjects received 20 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O5">
            <title>Neladenoson Bialanate 30 mg</title>
            <description>Subjects received 30 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O6">
            <title>Neladenoson Bialanate 40 mg</title>
            <description>Subjects received 40 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in 6-minute Walking Distance (6MWD) After 20 Weeks of Treatment</title>
          <description>The 6MWD test is designed to evaluate a subject's exercise capacity while performing an everyday activity.</description>
          <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure, and it also included subjects who were censored due to cardiovascular (CV) death or hospitalization for heart failure (HF) that prevented assessment of efficacy at 20 weeks.</population>
          <units>meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Value at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329" spread="95"/>
                    <measurement group_id="O2" value="306" spread="117"/>
                    <measurement group_id="O3" value="300" spread="109"/>
                    <measurement group_id="O4" value="328" spread="105"/>
                    <measurement group_id="O5" value="321" spread="101"/>
                    <measurement group_id="O6" value="363" spread="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="49.5"/>
                    <measurement group_id="O2" value="24.8" spread="72.4"/>
                    <measurement group_id="O3" value="27.2" spread="90.0"/>
                    <measurement group_id="O4" value="14.6" spread="54.1"/>
                    <measurement group_id="O5" value="16.3" spread="55.4"/>
                    <measurement group_id="O6" value="10.7" spread="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5183</p_value>
            <p_value_desc>Linear dose-response shape: The multiple comparison procedures (MCP) approach was applied to calculate the adjusted one-sided p-values of the contrast test.</p_value_desc>
            <method>MCP-Mod method</method>
            <method_desc>Dose response relationship was assessed using the MCP-Mod method combining MCP principles with modeling techniques.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3300</p_value>
            <p_value_desc>Sigmoidal Emax 1 dose-response shape: The MCP approach was applied to calculate the adjusted one-sided p-values of the contrast test.</p_value_desc>
            <method>MCP-Mod method</method>
            <method_desc>Dose response relationship was assessed using the MCP-Mod method combining MCP principles with modeling techniques</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6232</p_value>
            <p_value_desc>Sigmoidal Emax 2 dose-response shape: The MCP approach was applied to calculate the adjusted one-sided p-values of the contrast test.</p_value_desc>
            <method>MCP-Mod method</method>
            <method_desc>Dose response relationship was assessed using the MCP-Mod method combining MCP principles with modeling techniques</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0918</p_value>
            <p_value_desc>Emax dose-response shape: The MCP approach was applied to calculate the adjusted one-sided p-values of the contrast test.</p_value_desc>
            <method>MCP-Mod method</method>
            <method_desc>Dose response relationship was assessed using the MCP-Mod method combining MCP principles with modeling techniques</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2701</p_value>
            <p_value_desc>Quadratic dose-response shape: The MCP approach was applied to calculate the adjusted one-sided p-values of the contrast test.</p_value_desc>
            <method>MCP-Mod method</method>
            <method_desc>Dose response relationship was assessed using the MCP-Mod method combining MCP principles with modeling techniques</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Weekly Percentage of Maximum Possible Recorded Activity Intensity</title>
        <description>AVIVO™ Mobile Patient Management System, a wearable wireless device worn by the subject, was used to monitor subjects' cardiovascular status. The patient's everyday physical activity e.g. duration, intensity, was also tracked by the AVIVO device. For Activity Intensity, the Unit of Measure is &quot;percentage of maximum activity&quot;, and length of intervals is &quot;daily&quot;.</description>
        <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
        <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects received placebo matched to neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Neladenoson Bialanate 5 mg</title>
            <description>Subjects received 5 milligrams (mg) of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O3">
            <title>Neladenoson Bialanate 10 mg</title>
            <description>Subjects received 10 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O4">
            <title>Neladenoson Bialanate 20 mg</title>
            <description>Subjects received 20 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O5">
            <title>Neladenoson Bialanate 30 mg</title>
            <description>Subjects received 30 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O6">
            <title>Neladenoson Bialanate 40 mg</title>
            <description>Subjects received 40 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Weekly Percentage of Maximum Possible Recorded Activity Intensity</title>
          <description>AVIVO™ Mobile Patient Management System, a wearable wireless device worn by the subject, was used to monitor subjects' cardiovascular status. The patient's everyday physical activity e.g. duration, intensity, was also tracked by the AVIVO device. For Activity Intensity, the Unit of Measure is &quot;percentage of maximum activity&quot;, and length of intervals is &quot;daily&quot;.</description>
          <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure</population>
          <units>percentage of maximum activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Value at visit Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="1.03"/>
                    <measurement group_id="O2" value="2.76" spread="0.72"/>
                    <measurement group_id="O3" value="2.83" spread="0.95"/>
                    <measurement group_id="O4" value="2.51" spread="0.91"/>
                    <measurement group_id="O5" value="2.61" spread="0.94"/>
                    <measurement group_id="O6" value="2.43" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.58"/>
                    <measurement group_id="O2" value="-0.25" spread="0.51"/>
                    <measurement group_id="O3" value="-0.12" spread="0.58"/>
                    <measurement group_id="O4" value="-0.08" spread="0.67"/>
                    <measurement group_id="O5" value="-0.18" spread="0.57"/>
                    <measurement group_id="O6" value="-0.14" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measured Values (Log Transformed) and Absolute Change in NT-proBNP From Baseline to 20 Weeks</title>
        <description>NT-proBNP = N-terminal pro-hormone b-type natriuretic peptide</description>
        <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
        <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects received placebo matched to neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Neladenoson Bialanate 5 mg</title>
            <description>Subjects received 5 milligrams (mg) of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O3">
            <title>Neladenoson Bialanate 10 mg</title>
            <description>Subjects received 10 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O4">
            <title>Neladenoson Bialanate 20 mg</title>
            <description>Subjects received 20 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O5">
            <title>Neladenoson Bialanate 30 mg</title>
            <description>Subjects received 30 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O6">
            <title>Neladenoson Bialanate 40 mg</title>
            <description>Subjects received 40 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measured Values (Log Transformed) and Absolute Change in NT-proBNP From Baseline to 20 Weeks</title>
          <description>NT-proBNP = N-terminal pro-hormone b-type natriuretic peptide</description>
          <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure</population>
          <units>log (pg/ml)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Value at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="6.78" lower_limit="4.9" upper_limit="8.1"/>
                    <measurement group_id="O3" value="6.81" lower_limit="4.8" upper_limit="8.2"/>
                    <measurement group_id="O4" value="6.73" lower_limit="5.2" upper_limit="8.7"/>
                    <measurement group_id="O5" value="6.68" lower_limit="4.5" upper_limit="8.0"/>
                    <measurement group_id="O6" value="6.64" lower_limit="4.1" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute change from baseline to Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-1.3" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.08" lower_limit="-3.0" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.13" lower_limit="-1.7" upper_limit="1.6"/>
                    <measurement group_id="O4" value="0.06" lower_limit="-1.2" upper_limit="2.3"/>
                    <measurement group_id="O5" value="0.09" lower_limit="-1.3" upper_limit="0.9"/>
                    <measurement group_id="O6" value="0.19" lower_limit="-1.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measured Values (Log-transformed) and Absolute Change in High Sensitivity Troponin T (Hs-TNT) From Baseline to 20 Weeks</title>
        <description>High sensitivity troponin T (hs-TNT) was measured</description>
        <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
        <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects received placebo matched to neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Neladenoson Bialanate 5 mg</title>
            <description>Subjects received 5 milligrams (mg) of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O3">
            <title>Neladenoson Bialanate 10 mg</title>
            <description>Subjects received 10 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O4">
            <title>Neladenoson Bialanate 20 mg</title>
            <description>Subjects received 20 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O5">
            <title>Neladenoson Bialanate 30 mg</title>
            <description>Subjects received 30 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O6">
            <title>Neladenoson Bialanate 40 mg</title>
            <description>Subjects received 40 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measured Values (Log-transformed) and Absolute Change in High Sensitivity Troponin T (Hs-TNT) From Baseline to 20 Weeks</title>
          <description>High sensitivity troponin T (hs-TNT) was measured</description>
          <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure</population>
          <units>log(pg/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Value at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" lower_limit="1.9" upper_limit="4.4"/>
                    <measurement group_id="O2" value="3.25" lower_limit="1.9" upper_limit="4.7"/>
                    <measurement group_id="O3" value="2.95" lower_limit="1.9" upper_limit="4.7"/>
                    <measurement group_id="O4" value="2.76" lower_limit="1.9" upper_limit="4.2"/>
                    <measurement group_id="O5" value="2.73" lower_limit="1.9" upper_limit="3.9"/>
                    <measurement group_id="O6" value="2.76" lower_limit="1.9" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute change from baseline to Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-1.4" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.9" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-0.7" upper_limit="1.1"/>
                    <measurement group_id="O4" value="0.12" lower_limit="-0.8" upper_limit="1.5"/>
                    <measurement group_id="O5" value="0.13" lower_limit="-0.4" upper_limit="1.2"/>
                    <measurement group_id="O6" value="0.01" lower_limit="-0.8" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measured Values and Absolute Change in 3 Scores From Kansas City Cardiomyopathy Questionnaire (KCCQ) From Baseline to 20 Weeks: Overall Summary Score, Physical Limitation Score and Total Symptom Score</title>
        <description>The KCCQ is the leading health-related quality-of-life measure for patients with chronic heart failure (CHF). It is a 23-item questionnaire that independently measures the impact of patient's heart failure (HF), or its treatment, on 7 distinct domains: 1) Symptom Frequency 2) Symptom Burden 3) Physical Limitation 4) Quality of Life 5) Social Limitations 6) Self-efficacy 7) Symptoms Stability.
Overall summary score= mean score of (symptom frequency + symptom burden+ physical limitation + quality of life + social limitation); scores on a scale of 0 to 100, higher scores means better outcome; Physical Limitation: scores on a scale of 0 to 100, higher scores means better outcome; Total symptom score=mean score of (symptom frequency + symptom burden): scores on a scale of 0 to 100, higher scores means better outcome.
Positive change means improvement and negative change means deterioration.</description>
        <time_frame>Baseline, and up to 20 weeks of treatment</time_frame>
        <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects received placebo matched to neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Neladenoson Bialanate 5 mg</title>
            <description>Subjects received 5 milligrams (mg) of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O3">
            <title>Neladenoson Bialanate 10 mg</title>
            <description>Subjects received 10 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O4">
            <title>Neladenoson Bialanate 20 mg</title>
            <description>Subjects received 20 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O5">
            <title>Neladenoson Bialanate 30 mg</title>
            <description>Subjects received 30 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
          <group group_id="O6">
            <title>Neladenoson Bialanate 40 mg</title>
            <description>Subjects received 40 mg of neladenoson bialanate tablets orally for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measured Values and Absolute Change in 3 Scores From Kansas City Cardiomyopathy Questionnaire (KCCQ) From Baseline to 20 Weeks: Overall Summary Score, Physical Limitation Score and Total Symptom Score</title>
          <description>The KCCQ is the leading health-related quality-of-life measure for patients with chronic heart failure (CHF). It is a 23-item questionnaire that independently measures the impact of patient's heart failure (HF), or its treatment, on 7 distinct domains: 1) Symptom Frequency 2) Symptom Burden 3) Physical Limitation 4) Quality of Life 5) Social Limitations 6) Self-efficacy 7) Symptoms Stability.
Overall summary score= mean score of (symptom frequency + symptom burden+ physical limitation + quality of life + social limitation); scores on a scale of 0 to 100, higher scores means better outcome; Physical Limitation: scores on a scale of 0 to 100, higher scores means better outcome; Total symptom score=mean score of (symptom frequency + symptom burden): scores on a scale of 0 to 100, higher scores means better outcome.
Positive change means improvement and negative change means deterioration.</description>
          <population>Per-protocol set (PPS): Included all full analysis set (FAS) population subjects without validity findings for this outcome measure</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Summary Score Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.19" spread="18.02"/>
                    <measurement group_id="O2" value="64.75" spread="23.99"/>
                    <measurement group_id="O3" value="66.42" spread="21.21"/>
                    <measurement group_id="O4" value="64.57" spread="20.73"/>
                    <measurement group_id="O5" value="63.67" spread="17.76"/>
                    <measurement group_id="O6" value="64.65" spread="18.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Summary Score Change from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="13.55"/>
                    <measurement group_id="O2" value="7.04" spread="17.24"/>
                    <measurement group_id="O3" value="-1.33" spread="20.61"/>
                    <measurement group_id="O4" value="3.73" spread="13.03"/>
                    <measurement group_id="O5" value="0.27" spread="14.83"/>
                    <measurement group_id="O6" value="2.25" spread="14.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Limitation Score Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.07" spread="19.43"/>
                    <measurement group_id="O2" value="63.18" spread="25.24"/>
                    <measurement group_id="O3" value="68.03" spread="22.79"/>
                    <measurement group_id="O4" value="69.35" spread="22.64"/>
                    <measurement group_id="O5" value="64.53" spread="22.47"/>
                    <measurement group_id="O6" value="63.12" spread="23.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Limitation Score Change from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="17.54"/>
                    <measurement group_id="O2" value="1.40" spread="17.62"/>
                    <measurement group_id="O3" value="-1.34" spread="22.56"/>
                    <measurement group_id="O4" value="0.92" spread="14.65"/>
                    <measurement group_id="O5" value="-3.75" spread="22.10"/>
                    <measurement group_id="O6" value="2.17" spread="17.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Symptom Score Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.78" spread="19.64"/>
                    <measurement group_id="O2" value="72.25" spread="21.73"/>
                    <measurement group_id="O3" value="68.99" spread="23.13"/>
                    <measurement group_id="O4" value="69.99" spread="20.18"/>
                    <measurement group_id="O5" value="68.00" spread="20.09"/>
                    <measurement group_id="O6" value="71.03" spread="18.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Symptom Score Change from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="15.85"/>
                    <measurement group_id="O2" value="5.82" spread="17.51"/>
                    <measurement group_id="O3" value="0.14" spread="19.08"/>
                    <measurement group_id="O4" value="3.56" spread="14.04"/>
                    <measurement group_id="O5" value="2.54" spread="16.79"/>
                    <measurement group_id="O6" value="2.62" spread="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration up to 26 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subjects received placebo matched to neladenoson bialanate tablets orally for 20 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Neladenoson Bialanate 5mg</title>
          <description>Subjects received 5 mg of neladenoson bialanate tablets orally for 20 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Neladenoson Bialanate 10mg</title>
          <description>Subjects received 10 mg of neladenoson bialanate tablets orally for 20 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Neladenoson Bialanate 20mg</title>
          <description>Subjects received 20 mg of neladenoson bialanate tablets orally for 20 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Neladenoson Bialanate 30mg</title>
          <description>Subjects received 30 mg of neladenoson bialanate tablets orally for 20 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Neladenoson Bialanate 40mg</title>
          <description>Subjects received 40 mg of neladenoson bialanate tablets orally for 20 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza A virus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Insertion of ambulatory peritoneal catheter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hysterosalpingectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Material for public dissemination will be submitted to the Sponsor for review at least thirty (30) days prior to submission for publication, public dissemination, or review by a publication committee. If Sponsor does not respond within this period Institution and/or the Principal Investigator is/are free to proceed with the intended publication or presentation without further delay</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer</organization>
      <phone>1-888-8422937</phone>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

